| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/08/2001 | US6228849 Method for treating symptoms associated with premenstrual syndrome by administering a combination of calcium and vitamin D |
| 05/08/2001 | US6228848 3-(1-propen-3-oxo)-5,6-dihydronaphthalene derivatives; side effect reduction |
| 05/08/2001 | US6228847 Inhibitors of nucleoside metabolism |
| 05/08/2001 | US6228843 Method of using PKC inhibiting compounds to treat vascular disease |
| 05/08/2001 | US6228835 Decorin binding protein compositions |
| 05/08/2001 | US6228642 Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
| 05/08/2001 | US6228622 Fungicide for medical and agricultural use |
| 05/08/2001 | US6228619 Glucosaminidase |
| 05/08/2001 | US6228617 Nucleotide sequence coding a trigger chaperone protein; for use in screening bactericides |
| 05/08/2001 | US6228613 Stable factor VIII/von Willebrand factor complex |
| 05/08/2001 | US6228584 Nucleotide sequences for use in the detection of streptococcus |
| 05/08/2001 | US6228401 Processes for preparing flutamide compounds and compounds prepared by such processes |
| 05/08/2001 | US6228400 Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
| 05/08/2001 | US6228398 Dosage form for increasing patient compliance by reducing dosage frequency; attention deficit disorder, methylphenidate or salts |
| 05/08/2001 | US6228397 Pharmaceutical composition having two coating layers |
| 05/08/2001 | US6228395 Sustained-release microgranules containing Diltiazem as the active principle |
| 05/08/2001 | US6228394 Supercritical fluid extraction of mould lubricant from hard shell capsules |
| 05/08/2001 | US6228380 Delivery of hydroxy carboxylic acids |
| 05/08/2001 | US6228376 Adhesive cooling composition and process for its preparation |
| 05/08/2001 | US6228364 Isolation of polypeptides with sequences |
| 05/08/2001 | US6228362 Boron neutron capture therapy using pre-targeting methods |
| 05/08/2001 | US6228351 Medicated lip balm |
| 05/08/2001 | US6228347 Antioxidant gel for gingival conditions |
| 05/08/2001 | US6228346 Propellant mixtures and aerosols for micronizing medicaments with compressed gas |
| 05/08/2001 | CA2324484A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323464A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323191A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323183A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2199642C Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin |
| 05/08/2001 | CA2170289C A method of treating liver disease and like indications with vasodilating agents |
| 05/08/2001 | CA2167040C New alkylated (hetero)cyclic compounds; process for preparing the same and pharmaceutical compositions containing them |
| 05/08/2001 | CA2065412C Methods of preventing and reducing the size of striae distensae lesions |
| 05/08/2001 | CA2032330C Benzyl-substituted rhodanine derivatives for treating inflammatory bowel disease |
| 05/08/2001 | CA2032141C Pharmaceutically active agents that impede amyloid formation in vivo |
| 05/08/2001 | CA2029694C Heteroatoms-containing tricyclic compounds |
| 05/08/2001 | CA2027530C W-phenoxy-heterocyclic compounds |
| 05/08/2001 | CA2017746C A new phenylacetic derivative and process for their obtention |
| 05/08/2001 | CA2011896C Ringworm vaccine |
| 05/03/2001 | WO2001031343A2 Diagnosis and therapy of cancer using sgp28-related molecules |
| 05/03/2001 | WO2001031051A2 Antisense modulation of protein kinase c-theta expression |
| 05/03/2001 | WO2001031046A1 Invasive bacterial vectors for expressing alphavirus replicons |
| 05/03/2001 | WO2001031021A1 Multiple sclerosis-related superantigen |
| 05/03/2001 | WO2001031016A2 Processed human chemokines phc-1 and phc-2 |
| 05/03/2001 | WO2001031015A2 36p6d5: secreted tumor antigen |
| 05/03/2001 | WO2001031005A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 05/03/2001 | WO2001031003A1 Cloning, expression and characterisation of a gene expressed in tumour cells and involved in the regulation of the immune response |
| 05/03/2001 | WO2001030997A2 Microbe, microbial exopolysaccharide, and uses thereof |
| 05/03/2001 | WO2001030996A2 Microbial exopolysaccharide and uses thereof |
| 05/03/2001 | WO2001030979A1 Primary n-hydroxylamines |
| 05/03/2001 | WO2001030856A1 Molecularly imprinted polymers produced by template polymerisation |
| 05/03/2001 | WO2001030848A2 Nucleic acids of the human abc1 gene and applications thereof |
| 05/03/2001 | WO2001030847A1 Modified gp100 and uses thereof |
| 05/03/2001 | WO2001030828A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 05/03/2001 | WO2001030802A2 Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies |
| 05/03/2001 | WO2001030801A1 Antisense modulation of integrin-linked kinase expression |
| 05/03/2001 | WO2001030799A1 Methods to enhance and confine gene expression in cancer therapy |
| 05/03/2001 | WO2001030796A1 A process for preparing acarbose with high purity |
| 05/03/2001 | WO2001030795A1 Hygromycin derivatives |
| 05/03/2001 | WO2001030793A1 Hygromycin a prodrugs |
| 05/03/2001 | WO2001030790A1 Half-sandwich ruthenium (ii) compounds comprising nitrogen containing ligands for treatment of cancer |
| 05/03/2001 | WO2001030789A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 05/03/2001 | WO2001030784A1 Silicon compounds derived from ascorbic acid |
| 05/03/2001 | WO2001030781A2 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
| 05/03/2001 | WO2001030780A2 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| 05/03/2001 | WO2001030779A1 Naphthyridine derivatives |
| 05/03/2001 | WO2001030778A1 Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use |
| 05/03/2001 | WO2001030777A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | WO2001030776A1 Novel limonoids for use particularly in the treatment of cancer and method for producing the same |
| 05/03/2001 | WO2001030775A1 Novel indole compounds |
| 05/03/2001 | WO2001030774A1 Substituted indoles for modulating nfkb activity |
| 05/03/2001 | WO2001030772A1 Compounds and their use as cysteine protease inhibitors |
| 05/03/2001 | WO2001030768A1 Methods and compositions utilizing quinazolinones |
| 05/03/2001 | WO2001030767A1 Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist |
| 05/03/2001 | WO2001030766A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | WO2001030763A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 05/03/2001 | WO2001030761A1 Heterocyclically substituted benzoylguanidine, method for the production thereof, the use thereof as a medicament or means of diagnosis and a medicament containing the same |
| 05/03/2001 | WO2001030759A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | WO2001030758A1 Drugs for the treatment of malignant tumours |
| 05/03/2001 | WO2001030757A1 Drug discharge pump inhibitors |
| 05/03/2001 | WO2001030756A1 Benzamidine derivatives |
| 05/03/2001 | WO2001030752A2 Indole compounds for treating bacterial infections |
| 05/03/2001 | WO2001030750A1 Method of producing n-(4,5-bis-methanesulfonyl-2-methyl-benzoyl)-guanidine, the hydrochloride thereof |
| 05/03/2001 | WO2001030747A1 Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23 |
| 05/03/2001 | WO2001030745A1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase |
| 05/03/2001 | WO2001030736A2 Aromatic di-keto derivatives as glucose-6-phosphate translocase inhibitors |
| 05/03/2001 | WO2001030734A1 Novel hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 05/03/2001 | WO2001030448A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | WO2001030395A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 05/03/2001 | WO2001030394A1 Treatment of cancer |
| 05/03/2001 | WO2001030393A2 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products |
| 05/03/2001 | WO2001030391A2 Pharmaceutical composition containing midazolam |
| 05/03/2001 | WO2001030388A1 Tension-relieving agents for ciliary muscle |
| 05/03/2001 | WO2001030387A1 Preventives or remedies for arrhythmia |
| 05/03/2001 | WO2001030383A2 Medicament in order to induce tolerance |
| 05/03/2001 | WO2001030382A1 Method of inducing and/or enhancing an immune response to tumor antigens |
| 05/03/2001 | WO2001030381A2 Use of csf-1 inhibitors |
| 05/03/2001 | WO2001030379A2 Compositions and methods for preventing and treating transplant rejection |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030367A1 Platelet-activating factor antagonists and dermatological compositions for external use containing the same |
| 05/03/2001 | WO2001030362A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |